Early and sustained benefit on event-free survival and heart failure hospitalization from fixed-dose combination of isosorbide dinitrate/hydralazine: consistency across subgroups in the African-American Heart Failure Trial.

Taylor AL, Ziesche S, Yancy CW, Carson P, Ferdinand K, Taylor M, Adams K, Olukotun AY, Ofili E, Tam SW, Sabolinski ML, Worcel M, Cohn JN. Early and sustained benefit on event-free survival and heart failure hospitalization from fixed-dose combination of isosorbide dinitrate/hydralazine: consistency across subgroups in the African-American Heart Failure Trial. Circulation. 2007 Apr 03; 115(13):1747-53.

View in: PubMed

subject areas

authors with profiles

Elizabeth Ofili

RCMI CC is supported by the National Institute on Minority Health and Health Disparities, National Institutes of Health (NIH), through Grant Number U24MD015970. The contents of this site are solely the responsibility of the authors and do not necessarily represent the official views of the NIH

For technical support please contact support